This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The primary health outcome measurements were reduced mortality rate and probability of survival at 4 years. Further details of the analysis were not stated.
Effectiveness results
The use of thrombolytic therapy in the community before hospitalisation following myocardial infarction reduced mortality, in comparison with hospital thrombolysis, by 11% (95% CI: 1% -22%) at one year and 15% at 2.5 years. The probability of survival at four years was 0.65 for hospital therapy and 0.76 for community-based treatment.
Clinical conclusions
Thrombolytic therapy in the community reduces mortality and increases the probability of survival at 4 years compared with the comparator of hospital-based thrombolysis.
Measure of benefits used in the economic analysis
The measure of benefit was lives saved.
Direct costs
Direct costs included the cost of drugs (anistreplase, streptokinase and aspirin), labour costs including general practitioner training and visits, and capital (electrocardiograph and defibrillator). Costs and quantities were not reported separately. Discounting was applied at a rate of 6%. The source of resource use data was the clinical trial used for effectiveness data. The sources of cost data were not specifically stated.
Indirect Costs
Not done.
Currency

UK pounds sterling ().
Sensitivity analysis
The authors calculated a low and high estimate of costs for implementing community-based thrombolysis. The high cost assumed the procurement of new equipment and extended attendance times for GP visits, while the low cost assumed GPs would have already attended patients with suspected MI.
Estimated benefits used in the economic analysis
The use of thrombolytic therapy in the community before hospitalisation following myocardial infarction produces an additional probability of survival at four years of 11% (95% CI: 1% -22%) at four years in comparison with hospital thrombolysis.
Cost results
The cost per patient was between 510 (low estimate) and 970 (high estimate) for community-based treatment and 85 for the comparator of hospital thrombolysis. The discount rate was 6%.
Synthesis of costs and benefits
The costs and benefits were combined by means of a marginal cost per life saved summary measure. The results showed a marginal cost per life saved at four years by community thrombolysis to be 3,890 (1,990 to 42,820) for the low estimate, and 8,000 (4,100 to 88,100) for the high estimate.
